The upgraded facility marks a significant step in strengthening the nation’s capacity to support innovation, research, and ...

Well-known and respected business consulting and advisory firm Ocean Tomo reports that within the last quarter century, intellectual capital ...

First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 • Cadisegliatin intellectual property ...

Net loss: Tenax Therapeutics reported a net loss of $10.9 million for the second quarter of 2025, compared to a net loss of $3.6 million for second quarter of 2024.

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory ApprovalReceives $5.3 Million Installment from NIDA To Support Overdose Prote ...